Response Genetics Inc
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gast… Read more
Response Genetics Inc (RGDXQ) - Net Assets
Latest net assets as of March 2015: $-4.94 Million USD
Based on the latest financial reports, Response Genetics Inc (RGDXQ) has net assets worth $-4.94 Million USD as of March 2015.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.78 Million) and total liabilities ($15.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.94 Million |
| % of Total Assets | -45.81% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 224.67 |
Response Genetics Inc - Net Assets Trend (2005–2015)
This chart illustrates how Response Genetics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Response Genetics Inc (2005–2015)
The table below shows the annual net assets of Response Genetics Inc from 2005 to 2015.
| Year | Net Assets | Change |
|---|---|---|
| 2015-12-31 | $33.02 Million | +2921.71% |
| 2014-12-31 | $-1.17 Million | -120.32% |
| 2013-12-31 | $5.76 Million | +1162.12% |
| 2012-12-31 | $-542.21K | +91.17% |
| 2011-12-31 | $-6.14 Million | -87.39% |
| 2010-12-31 | $-3.28 Million | -604.51% |
| 2009-12-31 | $649.22K | -90.55% |
| 2008-12-31 | $6.87 Million | -54.51% |
| 2007-12-31 | $15.11 Million | +374.53% |
| 2006-12-31 | $-5.50 Million | -72.31% |
| 2005-12-31 | $-3.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Response Genetics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8424135900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2015)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $131.17 Million | 397.27% |
| Total Equity | $33.02 Million | 100.00% |
Response Genetics Inc Competitors by Market Cap
The table below lists competitors of Response Genetics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Idglobal Corp
PINK:IDGC
|
$0.98 |
|
China GengSheng Minerals Inc
PINK:CHGS
|
$0.98 |
|
Zhejiang Dashang Media Co. Ltd.
PINK:TKVR
|
$0.98 |
|
Universal Tracking Solutions Inc
PINK:UTRK
|
$0.98 |
|
Buzz Technologies Inc
PINK:BZTG
|
$0.98 |
|
MPM Technologies Inc
PINK:MPML
|
$0.98 |
|
Treasure Island Royalty Trust
PINK:TISDZ
|
$0.98 |
|
IFAN Financial Inc
PINK:IFAN
|
$0.98 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Response Genetics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2014 to 2015, total equity changed from -1,170,107 to 33,017,000, a change of 34,187,107.
- Net loss of 20,184,000 reduced equity.
- Other comprehensive income increased equity by 259,992.
- Other factors increased equity by 54,111,115.
Equity Change Factors (2014 to 2015)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.18 Million | -61.13% |
| Other Comprehensive Income | $259.99K | +0.79% |
| Other Changes | $54.11 Million | +163.89% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Response Genetics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $-1.17 | $0.00 | x |
| 2006-12-31 | $-2.02 | $0.00 | x |
| 2007-12-31 | $2.16 | $0.00 | x |
| 2008-12-31 | $0.67 | $0.00 | x |
| 2009-12-31 | $0.05 | $0.00 | x |
| 2010-12-31 | $-0.18 | $0.00 | x |
| 2011-12-31 | $-0.32 | $0.00 | x |
| 2012-12-31 | $-0.02 | $0.00 | x |
| 2013-12-31 | $0.17 | $0.00 | x |
| 2014-12-31 | $-0.03 | $0.00 | x |
| 2015-12-31 | $0.85 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Response Genetics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -61.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -111.88%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.48x
- Recent ROE (-61.13%) is above the historical average (-163.76%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 0.00% | 27.86% | 1.66x | 0.00x | $2.26 Million |
| 2006 | 0.00% | -22.56% | 0.73x | 0.00x | $-807.41K |
| 2007 | -33.45% | -64.87% | 0.32x | 1.62x | $-6.56 Million |
| 2008 | -138.05% | -133.13% | 0.53x | 1.97x | $-10.17 Million |
| 2009 | -1438.81% | -103.03% | 0.84x | 16.62x | $-9.41 Million |
| 2010 | 0.00% | -21.95% | 2.01x | 0.00x | $-4.34 Million |
| 2011 | 0.00% | -25.28% | 2.88x | 0.00x | $-5.11 Million |
| 2012 | 0.00% | -39.35% | 1.13x | 0.00x | $-7.32 Million |
| 2013 | -129.87% | -37.77% | 1.10x | 3.14x | $-8.06 Million |
| 2014 | 0.00% | -80.96% | 1.24x | 0.00x | $-13.42 Million |
| 2015 | -61.13% | -111.88% | 0.37x | 1.48x | $-23.49 Million |
Industry Comparison
This section compares Response Genetics Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $867,957,363
- Average return on equity (ROE) among peers: -141.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Response Genetics Inc (RGDXQ) | $-4.94 Million | 0.00% | N/A | $0.98 |
| Agilent Technologies Inc (A) | $4.57 Billion | 6.91% | 0.87x | $31.45 Billion |
| Amer Bio Medica (ABMC) | $-944.00K | 0.00% | 0.00x | $3.55K |
| ADCNF (ADCNF) | $612.34 Million | 111.18% | 6.93x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.64 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $4.37 Million | -93.77% | 0.93x | $36.19K |
| Avricore Health Inc (AVCRF) | $3.35 Million | -65.62% | 0.06x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $4.67 Million | -153.12% | 0.85x | $664.47K |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $48.86 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |